Canaccord Genuity Reiterates a 'Buy' on Dendreon (DNDN); MEDCAC Weighs In: Data Supports Provenge Utility
Tweet Send to a Friend
Canaccord Genuity reiterates a 'Buy' rating on Dendreon (NASDAQ: DNDN) and $65 price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
